HOME >> MEDICINE >> NEWS
ECP may be effective in treating Crohn's disease

(Washington, DC - May 23, 2007) -- Results from an international multi-center Phase II clinical trial suggest that extracorporeal photopheresis (ECP) may be effective in treating patients with clinically active (OR symptomatic) Crohns disease who cannot tolerate or are refractory to immunosuppressants and/or anti-TNF agents. A 50% response rate after 3 months of ECP treatment was noted in the study, using standard disease activity criteria, as presented this afternoon at a scientific research session of Digestive Disease Week (DDW). The majority of patients who responded to ECP therapy had a notable improvement in their disease symptoms and signs after only six weeks of treatment.

"We show in this pilot study that ECP is effective in patients with Crohn's disease (CD) that have previously failed the strongest therapies we currently have," explains Maria Abreu, MD, Associate Professor in The Henry D. Janowitz Division of Gastroenterology and in the Center for Immunobiology at The Mount Sinai Medical Center. ECP is believed to bolster tolerance in the immune system, which may be important in immune-mediated diseases such as Crohns. In contrast, most patients with inflammatory bowel disease are currently treated with medicines that suppress the immune system. Unlike ECP, those medications can have many serious side effects.

The 28 patient trial studied the safety and efficacy of ECP in patients with a Crohns Disease Activity Index (CDAI) of at least 220 and less than 450 indicating that at least moderately active symptomatic CD was present. Clinical response was defined as a CDAI decrease of 100 or greater from baseline and/or a CDAI of less than 150 at week 12. Patients received two treatments of ECP weekly from weeks 0-4 and two treatments every other week from weeks 6-12 with no infectious complications reported.

"The findings of our study suggest that Crohns disease patients who have not responded to other therapies may ben
'"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
25-May-2007


Page: 1 2

Related medicine news :

1. New treatment effective in counteracting cocaine-induced symptoms
2. Osteoporosis screening and treatment may be cost-effective for selected older men
3. Study shows radiofrequency ablation highly effective in treating kidney tumors
4. New study examines effectiveness of tailored health messages
5. Scaling up HIV prevention programs is cost effective
6. New study shows Rescue Remedy is an effective all-natural stress, anxiety reliever
7. U of M researchers assess effectiveness of computerized physician order entry system
8. Nepalese researchers identify cost-effective treatment for drug-resistant typhoid
9. Meningitis: effectiveness of preventive vaccination demonstrated
10. U-M study finds lymphoma drug effective over long term
11. Chemotherapy may enhance the effectiveness of brain tumor vaccines

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ECP may effective treating Crohn disease

(Date:5/18/2013)... CA (PRWEB) May 18, 2013 The topics ... classes are scrum framework, scrum roles, scrum meetings, scrum artifacts, ... units (8 PDUs) for attending them. , These trainings are ... It is also ideal for those who will be a ... or those who want to explore Agile and Scrum, but ...
(Date:5/18/2013)... According to the the Stevens Johnson Syndrome Foundation, ... is a severe allergic reaction usually to medicine (i). ... can quickly advance causing blistering and large areas of dead ... SJS can develop at any time and seriously affect both ... Manute Bol, passed away after he received kidney medicine which ...
(Date:5/17/2013)... YORK, May 18, 2013. Chronic trauma can inflict lasting ... Previous imaging studies of people with post-traumatic stress disorder, ... over-or under-react in response to stressful tasks, such as ... of a threatening face. Now, researchers at NYU School ... happens in the brains of combat veterans with PTSD ...
(Date:5/17/2013)... Stryker hip lawsuit claims filed ... ABG II Modular-Neck Hip Stem recall continue to move forward ... According to court documents, a Case Management Conference was held ... which time the Court, among other things, set deadlines by ... submit Fact Sheets to Defendant and Liaison Counsel. The ...
(Date:5/17/2013)... Martinson-Nicholls new slip-resistant stair treads ... renovation tread used on steps that require an ... renovation projects, our treads and nosings deliver maximum ... compliment building designs. Bold Step is strong enough ... stairs such as basement or deck steps. , ...
Breaking Medicine News(10 mins):Health News:Affordable Scrum Trainings In Irvine by Conscires Agile Practices 2Health News:Affordable Scrum Trainings In Irvine by Conscires Agile Practices 3Health News:Injury Law Firm Announces New Informative Graphic on Common Medicines That Have Allegedly Been Linked to Stevens Johnson Syndrome 2Health News:For combat veterans suffering from post-traumatic stress disorder, 'fear circuitry' in the brain never rests 2Health News:Stryker Hip Lawsuit News: Bernstein Liebhard LLP Reports on Recent Case Management Conference in New Jersey Stryker Hip Recall Litigation 2Health News:Stryker Hip Lawsuit News: Bernstein Liebhard LLP Reports on Recent Case Management Conference in New Jersey Stryker Hip Recall Litigation 3Health News:New Bold Step Renovation Stair Treads and Nosings from Martinson-Nicholls Add Slip Resistance to Stairs 2
(Date:5/16/2013)... and ZURICH , May 17, 2013 /PRNewswire/ ... Science, Technology and Research (A*STAR) and Switzerland,s ... volunteer has been dosed in a Phase 1 clinical trial ... bacteriophage Qbeta virus-like particle (VLP) technology. In this first Phase ... vaccine candidate and its potential to protect against H1N1 influenza ...
(Date:5/16/2013)... -- Nektar Therapeutics, (Nasdaq: NKTR ) President and Chief ... scheduled to present at the upcoming 2013 UBS Global Healthcare ... Sheraton New York Hotel on Tuesday, May 21, 2013 at ... accessible via a Webcast through a link posted in the ... http://www.nektar.com . This Webcast will be available for replay until ...
(Date:5/16/2013)... 2013  Alere Inc. (NYSE: ALR ), a ... health at home through the merger of rapid diagnostics and ... share on its Series B Convertible Perpetual Preferred Stock (NYSE: ... holders of record of Series B stock at the close ... will cover the amount of all dividends accrued from April ...
Breaking Medicine Technology:A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City 2
Cached News: